# Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma

> **NCT00844883** · PHASE2 · COMPLETED · sponsor: **Yale University** · enrollment: 50 (actual)

## Conditions studied

- Hepatocellular Carcinoma
- Hepatoma

## Interventions

- **DRUG:** sorafenib
- **PROCEDURE:** LC Bead-TACE

## Key facts

- **NCT ID:** NCT00844883
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2021-11-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00844883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00844883, "Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00844883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*